Geno Germano is a member of the Precision BioSciences Board of Directors and a 30-year veteran of the pharmaceutical and life sciences industry who, prior to joining Elucida Oncology as Chief Executive Officer, served in multiple Executive roles at Intrexon Corporation, Pfizer Inc., Wyeth, and Johnson & Johnson.
At Pfizer, he led the Global Innovative Pharmaceutical business, cultivating a $14 billion operation and guiding the development of an extensive portfolio of products in the cardiovascular, immunology, metabolic disease, neuroscience, and rare disease areas. He also served as Pfizer’s President and General Manager of the Specialty Care, Vaccines, and Oncology business units.
At Wyeth Pharmaceuticals, Mr. Germano served as President of Wyeth U.S., President of the Global Pharmaceutical and Women’s Healthcare business, and as Executive Vice President of the Vaccines Business. He has been a member of the Group of Fifty (G50) and served on the Board of the Biotechnology Innovation Organization, where he was a member of the Executive Committee and Chairman of the International Committee. Mr. Germano also previously served on the Advisory Board of the Healthcare Businesswomen’s Association and as a Director of The Medicines Company and Bioverativ. He was formerly a Trustee of the Albany College of Pharmacy and Health Sciences. He is currently a Director of Sage Therapeutics and Chairman of its Nominating and Governance Committee. He received his Bachelor of Science degree at the Albany College of Pharmacy and Health Sciences.
What is Geno J. Germano's net worth?
The estimated net worth of Geno J. Germano is at least $330 thousand as of March 9th, 2026. Mr. Germano owns 40,000 shares of Precision BioSciences stock worth more than $330,000 as of July 16th. This net worth estimate does not reflect any other investments that Mr. Germano may own. Learn More about Geno J. Germano's net worth.
How do I contact Geno J. Germano?
Has Geno J. Germano been buying or selling shares of Precision BioSciences?
Geno J. Germano has not been actively trading shares of Precision BioSciences over the course of the past ninety days. Most recently, on Tuesday, December 16th, Geno J. Germano bought 3,000 shares of Precision BioSciences stock. The stock was acquired at an average cost of $4.72 per share, with a total value of $14,160.00. Following the completion of the transaction, the director now directly owns 23,883 shares of the company's stock, valued at $112,727.76. Learn More on Geno J. Germano's trading history.
Who are Precision BioSciences' active insiders?
Are insiders buying or selling shares of Precision BioSciences?
In the last twelve months, Precision BioSciences insiders bought shares 5 times. They purchased a total of 11,181 shares worth more than $53,978.57. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 98,557 shares worth more than $407,257.82. The most recent insider tranaction occured on February, 18th when CEO Michael Amoroso sold 20,559 shares worth more than $78,946.56. Insiders at Precision BioSciences own 2.7% of the company.
Learn More about insider trades at Precision BioSciences. Information on this page was last updated on 2/18/2026.
